宏达高科(002144) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥165,356,633.86, representing a 9.16% increase year-over-year[4] - Net profit attributable to shareholders for Q3 2022 was ¥31,452,693.91, a significant increase of 51.15% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥28,976,162.38, up 70.43% year-over-year[4] - The basic earnings per share for Q3 2022 was ¥0.1779, an increase of 51.15% compared to the same period last year[4] - The net profit for Q3 2022 was CNY 74,715,567.56, a decrease of 24.0% compared to CNY 98,263,449.89 in Q3 2021[17] - The total comprehensive income for the period was CNY 59,262,567.56, compared to CNY 97,233,249.89 in Q3 2021, reflecting a decline of 38.9%[17] - Basic and diluted earnings per share were both CNY 0.4221, down from CNY 0.5550 in the previous year[17] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥2,129,783,164.78, reflecting a 2.09% increase from the end of the previous year[4] - Total assets as of September 30, 2022, were CNY 2,129,783,164.78, up from CNY 2,086,217,456.64 at the beginning of the year[15] - Current assets totaled CNY 801,892,253.80, an increase from CNY 733,315,634.29, indicating improved liquidity[14] - The company reported a decrease in financial liabilities, with total liabilities at CNY 224,689,698.07 compared to CNY 223,460,304.69 previously[15] - The equity attributable to shareholders rose to CNY 1,900,836,577.69 from CNY 1,859,360,967.15, reflecting a solid capital position[16] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥41,236,447.87, down 46.14% compared to the previous year[4] - The net cash flow from operating activities was CNY 41,236,447.87, down 46.1% from CNY 76,565,219.90 in the same period last year[19] - The cash flow from investment activities was CNY 60,961,037.75, a decrease of 48.0% compared to CNY 117,324,507.81 in the previous year[19] - The cash flow from financing activities showed a net outflow of CNY 16,926,252.80, compared to an outflow of CNY 17,676,252.80 in the same period last year[20] - Cash and cash equivalents increased to CNY 488,295,827.01 from CNY 409,598,208.04, enhancing the company's cash position[14] - Cash and cash equivalents at the end of the period totaled CNY 482,704,973.75, an increase from CNY 460,278,976.67 at the end of Q3 2021[20] Operating Performance - Total operating revenue for the third quarter was CNY 438,780,176.46, a slight increase from CNY 436,132,541.05 in the previous year[16] - Total operating costs decreased to CNY 377,270,413.47 from CNY 393,713,036.55, reflecting a cost reduction strategy[16] - Research and development expenses were CNY 15,872,650.55, down from CNY 22,915,345.49, indicating a focus on efficiency[16] - The total revenue from operating activities was CNY 403,090,817.01, an increase of 7.7% from CNY 374,262,243.88 in the previous year[19] Investment Activities - The company achieved an investment income of CNY 21,057,766.02, down from CNY 30,278,223.84, suggesting a need for strategic review in investment activities[16] - The company received CNY 750,000.00 from investment activities during the quarter, with no previous year comparison available[20] Subsidiary Establishment - The company established a wholly-owned subsidiary, Zhejiang Weierde Smart Medical Co., Ltd., with a registered capital of ¥20 million, focusing on the production and sales of medical devices[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,826[10]